权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing Synthetic Enzymes to Treat Inborn Errors of Metabolism

开发合成酶来治疗先天性代谢缺陷

基本信息

批准号：
10540317
负责人：
Nikhil Unni Nair
金额：
$ 15.37万
依托单位：
TUFTS UNIVERSITY MEDFORD
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-12-13 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10540317
关键词：
Acute Adolescent Adult Amino Acids Amino Acids Activation Ammonia Anabolism Animals Biochemistry Branched-Chain Amino Acids Caregivers Child Chronic Clinical Computer Analysis Computer Models Computer Simulation Data Deamination Descriptor Development Diet Directed Molecular Evolution Disease Distal Drug Kinetics Engineering Enzymes Family Formulation Foundations Funding Mechanisms Goals Grant Inborn Errors of Metabolism Individual Infant Infection Injectable Isoleucine Keto Acids Kinetics Lead Leucine Libraries Lyase Maple Syrup Urine Disease Metabolic Metabolism Modality Modeling Monitor Mutagenesis Mutation Nature Neurologic Newborn Infant Nutrient Outcome Oxidoreductase Pathology Pathway interactions Patients Pharmaceutical Preparations Pharmacodynamics Phenylalanine Phenylalanine Ammonia-Lyase Phenylketonurias Probability Property Protein Engineering Protein-Restricted Diet Quality of life Quantum Mechanics Reaction Residual state Resolution Site Supplementation System Techniques Technology Testing Thermodynamics Toxic effect Valine Variant Work amino acid therapy cofactor design dietary restriction enzyme activity enzyme model enzyme replacement therapy enzyme substrate complex high throughput screening improved innovation isovaleric acidemia molecular mechanics novel programs risk mitigation simulation success synthetic enzyme therapeutic development translational potential

项目摘要

Project Summary. The severe, acute, and chronic developmental and neurological impacts seen in branched chain ketoacid dehydrogenase deficient Maple Syrup Urine Disease (BCKD-deficient MSUD) and isovaleryl‐CoA dehydrogenase deficient Isovaleric Acidemia (IVD-deficient IVA) seen in newborns are due to the presence of high concentrations of leucine, isoleucine, and valine in their system. Patients with these disorders are limited to manage their condition though a low-protein diet and nutrient supplementation, which is often inadequate, difficult to adhere to, and can still lead to metabolic decompensation. Management strategies include reduction and restriction of toxic metabolites and substrates, promotion of anabolism and stimulation of residual enzyme activity along with activation of amino acid and ketoacid scavenging pathways. Even then, the quality of life of patients is poor, as is for their caregivers since patients need to be monitored closely to avoid metabolic crisis precipitated either by infection, diet, or other reasons. Thus, there is significant need for new medications that can benefit infants, children, adolescents, and adults. This work is based on the hypothesis that high systemic concentrations of offending amino acid(s) in patients can be reduced using high activity enzymes, in a manner like how Pegvaliase reduces phenylalanine concentrations in phenylketonuria (PKU) patients. Core to this work is implementation of a twofold approach that combines experimental directed evolution techniques and computations enzyme design.

项目总结。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Towards universal synthetic heterotrophy using a metabolic coordinator.

使用代谢协调器实现通用合成异养。

DOI：
10.1016/j.ymben.2023.07.001
发表时间：
2023
期刊：
Metabolic engineering
影响因子：
8.4
作者：
Sullivan,SeanF;Shetty,Anuj;Bharadwaj,Tharun;Krishna,Naveen;Trivedi,VikasD;EndalurGopinarayanan,Venkatesh;Chappell,ToddC;Sellers,DanielM;PravinKumar,R;Nair,NikhilU
通讯作者：
Nair,NikhilU